Cretostimogene Grenadenorepvec

Phase 3

CG Oncology, Inc. (CGON)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q1 '27

CGONPhase 2$5.4B

Cretostimogene Grenadenorepvec Phase 2 Est. Readout

Cretostimogene Grenadenorepvec• High-Risk Non-Muscle-Invasive Bladder Cancer325

Q1 2027~QConfirmed

CT.gov

00%

Q1 '27

CGONPhase 3$5.4B

Cretostimogene Grenadenorepvec Phase 3 Est. Readout

Cretostimogene Grenadenorepvec• High-Risk Non-Muscle-Invasive Bladder Cancer367

Q1 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in High-Risk Non-Muscle-Invasive Bladder Cancer

View Full Landscape

Drug Information

Target Indication

High-Risk Non-Muscle-Invasive Bladder Cancer

Clinical Trial

NCT06567743

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CGON

CG Oncology, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

CG0070Phase 2

Non Muscle Invasive Bladder Cancer

IvaltinostatPhase 2

Metastatic Pancreatic Adenocarcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts